Plus Therapeutics announced that the company’s Board of Directors has approved a reverse stock split of its shares of common stock at a ratio of 1-for-15. The reverse stock split will become effective at 12:01 a.m. Eastern Time on May 1, 2023, and the company’s common stock will open for trading on The Nasdaq Capital Market on a post-split basis on May 1, 2023 under the company’s existing trading symbol, "PSTV." At such time, the company’s common stock will also commence trading with a new CUSIP number, 72941H509. The reverse stock split is being implemented to increase the per share trading price of the company’s common stock for the purpose of ensuring a share price high enough to comply with the minimum $1.00 bid price requirement for continued listing on The Nasdaq Capital Market.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on PSTV:
- Plus Therapeutics Announces Reverse Stock Split
- Plus Therapeutics reports Q1 EPS (14c), consensus (13c)
- Plus Therapeutics Reports First Quarter 2023 Financial Results and Business Highlights
- Plus Therapeutics Completes Enrollment of the Original Three Patients Required for Cohort 8 of ReSPECT-GBM Phase 1/2a Trial
- Plus Therapeutics completes enrollment in Cohort 8 of ReSPECT-GBM Phase 1/2a